Advanced Cholangiocarcinoma Clinical Trial
Official title:
A Phase Ⅱ, Open Label, Single-center Study of Lenvatinib and Tirelizumab Combined With Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma
Verified date | October 2023 |
Source | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Cholangiocarcinoma (CCA) is a heterogeneous group of cancers arising from the epithelial cells of bile ducts. Because of highly aggressive malignancy, most of the patients are diagnosed at an advanced stage and lose the chance to undergo surgery. As more effective and novel chemotherapy, targeted therapies, and immunotherapy become available, multiple treatments can be chosen for the patients with advanced CCA. Cytotoxic cell death during tumor chemotherapy triggers antigen release and induces strong anti-tumor effects of T cells. Tyrosine kinase inhibitors (TKI) can reduce the expression of PD-L1 and inhibit Treg cell infiltration, and together with immune checkpoint inhibitors, they can relieve tumor immunosuppressive microenvironment. Therefore,we aim to investigate the safety and efficacy of lenvatinib, tislelizumab combined with gemcitabine plus cisplatin (GPLET) in the treatment of advanced cholangiocarcinoma.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | August 31, 2028 |
Est. primary completion date | August 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: - Histologically proven, unresectable advanced or metastatic cholangiocarcinoma patients. - the world health organization (WHO)/ECOG physical state (PS) to 0 or 1. - at least 1 RECIST 1.1 standard target lesions. - not previously received immunotherapy, including but not limited to CTLA 4, PD-L1 or/and PD-1 inhibitors. - adequate organ and bone marrow function, defined as follows: 9.0 g/dL or higher hemoglobin; neutrophil count 1.5 x 109 / L; platelet count 100 x 109 / L. Exclusion Criteria: - Active or previously documented autoimmune disease or inflammatory disease. - Uncontrolled complications. - History of other primary malignancies. - Active infection. - Women who are pregnant or breastfeeding. |
Country | Name | City | State |
---|---|---|---|
China | The Second Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
Second Affiliated Hospital, School of Medicine, Zhejiang University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | objective remission rate (ORR) | According to RECIST v1.1, the proportion of patients with at least one complete response (CR) or partial response (PR) (%) | 4 cycle treatment (each cycle is 21 days) | |
Secondary | progression-free survival (PFS) | The time between the date of randomization and the date of radiographic progression as defined by RECIST1.1 | From date of randomization until the date of first documented progression, assessed up to 60 months | |
Secondary | Overall survival time (OS) | The time between the date of randomization and death from any cause | From date of randomization until the date of death from any cause, assessed up to 60 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05823311 -
Lenvatinib, Tislelizumab Combined With Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma
|
Phase 3 | |
Not yet recruiting |
NCT06439485 -
Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion
|
Phase 2 | |
Recruiting |
NCT06420349 -
NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma
|
Phase 1 | |
Recruiting |
NCT05727176 -
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
|
Phase 2 | |
Recruiting |
NCT05791448 -
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
|
Phase 1 | |
Active, not recruiting |
NCT04093362 -
Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
|
Phase 3 | |
Recruiting |
NCT03996408 -
Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma
|
Phase 1/Phase 2 | |
Terminated |
NCT02982720 -
Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron
|
Phase 2 | |
Terminated |
NCT02150967 -
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
|
Phase 2 | |
Recruiting |
NCT03982680 -
Toripalimab Combined With Gemcitabine/5--fluoropyrimidine for Advanced Cholangiocarcinoma
|
Phase 2 | |
Terminated |
NCT04088188 -
Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma
|
Phase 1 | |
Completed |
NCT02989857 -
Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)
|
Phase 3 | |
Recruiting |
NCT05805956 -
IMM2902 in Patients With Advanced Solid Tumors Expressing HER2
|
Phase 1/Phase 2 | |
Terminated |
NCT03773302 -
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
|
Phase 3 | |
Approved for marketing |
NCT04507503 -
Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
|